Anil Kapur - Actinium Pharmaceuticals Chief Commercial Officer
| ATNM Stock | USD 6.85 0.18 2.70% |
Executive
Mr. Anil Kapur is Chief Commercial Officer of the Company. Mr. Kapur joined Actinium in February 2018 from BristolMyers Squibb, where he was the Vice President, Head of Early Assets, Biomarkers External Innovation within the Worldwide Oncology Commercialization organization and helped advance the companys leading ImmunoOncology portfolio. Prior to this position, he was the Vice President Global Head, Oncology Commercial Portfolio Product Strategy at Baxalta and a member of the Oncology Leadership Team. In this role, Mr. Kapur also led the Joint Strategic Committees responsible for advancing the early ImmunoOncology partnerships with Symphogen and the allogeneic CART partnership with Precision BioSciences. Mr. Kapur built a distinguished career spanning 15 years at Johnson Johnson where in his last role, he served as the Vice President, Commercial Leader for the Hematology Franchise with responsibility for the development and execution of global commercial strategy and launch plans for all Hematology inmarket, latestage development, and early pipeline assets. He is credited with significantly shaping the clinical development plans and successful launch and growth of multiple Oncology blockbuster products including IMBRUVICA, DARZALEX, and VELCADE. At JJ, he led the IMBRUVICA Joint Commercial Committee, established between JJ and Pharmacyclics, and built and led the global team that launched DARZALEX, the first biologic for Multiple Myeloma. Anil also held leadership roles of increasing complexity and responsibility in US Marketing, US Regional Sales, and within the AsiaPacific Regional Oncology organization covering 14 markets including Japan, China, Australia and Korea since 2018.
| Age | 65 |
| Tenure | 6 years |
| Professional Marks | MBA |
| Address | 100 Park Avenue, New York, NY, United States, 10017 |
| Phone | 646 677 3870 |
| Web | https://www.actiniumpharma.com |
Actinium Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.3317) % which means that it has lost $0.3317 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9492) %, meaning that it created substantial loss on money invested by shareholders. Actinium Pharmaceuticals' management efficiency ratios could be used to measure how well Actinium Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 19th of April 2024, Return On Tangible Assets is likely to grow to -0.57. In addition to that, Return On Capital Employed is likely to grow to -0.68. At this time, Actinium Pharmaceuticals' Total Assets are very stable compared to the past year. As of the 19th of April 2024, Total Current Assets is likely to grow to about 82.2 M, though Non Currrent Assets Other are likely to grow to (0.95).Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Dana Lynch | Adaptimmune Therapeutics Plc | N/A | |
| MD BA | Adaptimmune Therapeutics Plc | 60 | |
| Robyn Hunter | Fortress Biotech | 62 | |
| Nathalie DuboisStringfellow | Sangamo Therapeutics | 62 | |
| Adam Waldman | TG Therapeutics | N/A | |
| Ronil MS | Ocuphire Pharma | N/A | |
| Carlo Tanzi | Seres Therapeutics | N/A | |
| Stephanie Diaz | Viking Therapeutics | N/A | |
| Clint Wallace | Madrigal Pharmaceuticals | N/A | |
| PharmD MBA | Madrigal Pharmaceuticals | N/A | |
| Nelson Cabatuan | Rigel Pharmaceuticals | 39 | |
| Laura Dillard | Exelixis | N/A | |
| David Ojala | Sangamo Therapeutics | N/A | |
| Lisa MD | Seres Therapeutics | 65 | |
| Nirav CFA | Ocuphire Pharma | N/A | |
| Ferdinand Verdonck | Affimed NV | 76 | |
| Robert MD | BioXcel Therapeutics | N/A | |
| Michael PharmD | Cassava Sciences | N/A | |
| Brian JD | Madrigal Pharmaceuticals | 62 | |
| Eric Schoen | Cassava Sciences | 56 | |
| Calais Pharm | Transcode Therapeutics | 65 | |
Management Performance
| Return On Equity | -0.95 | ||||
| Return On Asset | -0.33 |
Actinium Pharmaceuticals Leadership Team
Elected by the shareholders, the Actinium Pharmaceuticals' board of directors comprises two types of representatives: Actinium Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Actinium. The board's role is to monitor Actinium Pharmaceuticals' management team and ensure that shareholders' interests are well served. Actinium Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Actinium Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Nitya Ray, Executive Vice President Head - Product Development, Manufacturing and Supply Chain | ||
| Qing Liang, VP Sciences | ||
| Dale Ludwig, Chief Scientific Officer | ||
| Sergio Traversa, Interim CFO, Independent Director | ||
| Dragan Cicic, COO, Chief Medical Officer | ||
| Jenny Hsieh, Chief Officer | ||
| Sunitha Lakshminarayanan, Head VP | ||
| Cynthia Pussinen, Executive Vice President - Technical Operations and Supply Chain | ||
| Kaushik Dave, President CEO, Director | ||
| Anil Kapur, Chief Commercial Officer | ||
| MS MBA, Chairman CEO | ||
| David Nicholson, Independent Director | ||
| Jehan Rowlands, Vice President and Head - Regulatory Affairs | ||
| Robert Daly, Vice President Head - Clinical Operations | ||
| Niva Almaula, Chief Business Officer | ||
| Steven BS, CFO Secretary | ||
| Steven Price, Vice President - Clinical and Commercial Strategy | ||
| Sandesh Seth, Chairman of the Board | ||
| MBA MS, Chairman CEO | ||
| Bernie PMP, Executive Management | ||
| Paul Esq, Vice Counsel | ||
| Dr MS, VP Operations | ||
| Steve OLoughlin, Principal Financial and Accounting Officer | ||
| Vijay Reddy, Vice President Clinical Development | ||
| CDavid Nicholson, Lead Independent Director | ||
| Mamata Gokhale, Vice President Global Head of Regulatory Affairs | ||
| Arun Swaminathan, Chief Officer | ||
| Elaina Haeuber, VP Operations | ||
| Ajit Shetty, Independent Director | ||
| Richard Steinhart, Director | ||
| C Nicholson, Independent Director | ||
| Mark Berger, Chief Medical Officer | ||
| David Gould, Senior Affairs | ||
| Jeffrey Chell, Independent Director | ||
| Qing Ling, Vice President Head of Radiation Sciences | ||
| Avinash MD, Chief Officer |
Actinium Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Actinium Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.95 | ||||
| Return On Asset | -0.33 | ||||
| Operating Margin | (127.69) % | ||||
| Current Valuation | 121.51 M | ||||
| Shares Outstanding | 29.4 M | ||||
| Shares Owned By Insiders | 2.16 % | ||||
| Shares Owned By Institutions | 24.63 % | ||||
| Number Of Shares Shorted | 2.19 M | ||||
| Price To Earning | (1.45) X | ||||
| Price To Book | 7.27 X |
Pair Trading with Actinium Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Actinium Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Actinium Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Actinium Stock
| 0.43 | LPTX | Leap Therapeutics Financial Report 20th of May 2024 | PairCorr |
The ability to find closely correlated positions to Actinium Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Actinium Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Actinium Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Actinium Pharmaceuticals to buy it.
The correlation of Actinium Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Actinium Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Actinium Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Actinium Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Actinium Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Actinium Stock, please use our How to Invest in Actinium Pharmaceuticals guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Complementary Tools for Actinium Stock analysis
When running Actinium Pharmaceuticals' price analysis, check to measure Actinium Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Actinium Pharmaceuticals is operating at the current time. Most of Actinium Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Actinium Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Actinium Pharmaceuticals' price. Additionally, you may evaluate how the addition of Actinium Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |
Is Actinium Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Actinium Pharmaceuticals. If investors know Actinium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Actinium Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.83) | Revenue Per Share 0.003 | Quarterly Revenue Growth (1.00) | Return On Assets (0.33) | Return On Equity (0.95) |
The market value of Actinium Pharmaceuticals is measured differently than its book value, which is the value of Actinium that is recorded on the company's balance sheet. Investors also form their own opinion of Actinium Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Actinium Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Actinium Pharmaceuticals' market value can be influenced by many factors that don't directly affect Actinium Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Actinium Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Actinium Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Actinium Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.